ClinicalTrials.gg
TerminatedNCT04102124Updated Jun 24, 2025

A Study of SHR3680 in Combination With SHR3162 in the Treatment of mCRPC

A Phase 2 interventional study of SHR3680 and SHR3162 in Prostate Cancer and Castration-resistant Prostate Cancer, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Terminated at 1 site in China. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-24.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 2, Interventional, and Treatment

Why this study was terminated
The sponsor's R\&D strategy is adjusted.

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Apr 2019, registered Sep 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 18 studies testing rezvilutamide in Prostatic Neoplasms — 10 open to participants now, 11 under way, 3 of them phase 3. rezvilutamide · Prostatic Neoplasms.

Enrollment
15th of 18
20 · median 98
Started
2019
the only one that year
Phase 2
7 of 18
5 open now
Registered
4th of 18
by date
Lead sponsor
9 of 18
Jiangsu HengRui Medicine Co., Ltd.

Among the 18 studies testing rezvilutamide in Prostatic Neoplasms, this one is the 15th largest by enrollment, is the only one that started in 2019, is one of 7 in phase 2, and was the 4th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

10 of the 18 studies testing rezvilutamide in Prostatic Neoplasms are open now, in 1 country. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

About rezvilutamide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing rezvilutamide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The aim of this trial is to evaluate SHR3680 combined with SHR3162 and SHR3680 single drug to improve Metastatic Castration Resistant Prostate Cancer Patients whether the patient's overall survival (OS) is superior to placebo.

Read the detailed description

This is a multicenter, randomized , double-blind Phase II trial and the aim of this trial is to evaluate SHR3680 combined with SHR3162 and SHR3680 single drug to improve Metastatic Castration Resistant Prostate Cancer Patients Previously Treated With Abiraterone and Docetaxel whether the patient's overall survival (OS) is superior to placebo. The Stage I part is a dose-escalation and -expansion study. Approximately 18\~24 patients in Stage I will receive fixed-dose of orally SHR3680 and only one of two dose levels of orally SHR3162. The Primary endpoints of the Stage I are incidence of adverse events(AE) and recommended phase 2 dose(RP2D). The Stage II part is a randomized , double-blind study. Approximately 90\~120 patients in Stage II will receive SHR3162 combined with SHR3680, in which one fixed-dose levels of SHR3162 will be selected based on the result of the Stage I.The Primary endpoint of the Stage II is overall survival(OS).

03

Conditions studied

  • Prostate Cancer
  • Castration-resistant Prostate Cancer

Browse trials for

Keywords

  • Castration-resistant Prostate Cancer
  • SHR3680
  • SHR3162
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. or cytologically confirmed prostate cancer; does not suggest neuroendocrine or small cell characteristics
  2. (ECOG) Performance Status (PS) of 0 or 1;
  3. Radiographic evidence of ;
  4. Sustained therapy of luteinizing hormone-releasing hormone analogue(LHRHA)or received bilateral orchiectomy; patients who did not receive bilateral orchiectomy are willing to receive sustained therapy of LHRHA;
  5. Evidence of prostate cancer progression under the sustained therapy of LHRHA or bilateral orchiectomy;
  6. Adequate hepatic, renal, heart, and hematological functions;
  7. Patients have given voluntary written before performance of any study-related procedure not part of normal medical care,with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care.
  8. Patient has been treated with Abiraterone and treatment failed(Treatment failure is defined as the progression of disease during treatment)
  9. Patient has been treated with Docetaxel and treatment failed or can not tolerate docetaxel chemotherapy or patients who are not suitable for docetaxel treatment at the time of screening.

Exclusion criteria

Exclusion Criteria:

  1. Have received any anti-tumor therapy in the past 4 weeks,including radiotherapy, chemotherapy, operation, targeted therapy, immuntherapy, and endocrinotherapy;
  2. Planned to initiate any other anti-tumor therapies during the study;
  3. Unable to swallow, chronic diarrhea and intestinal obstruction, or the presence of a variety of other factors that affect drug use and absorption;
  4. cardiovascular diseases;
  5. History of seizure or certain conditions that may predispose to seizure;
  6. Severe concurrent disease and infection that, in the judgment of the investigator, would make the patient inappropriate for enrollment.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    SHR3680+SHR3162

    Participants will receive SHR3680 combined with SHR3162 orally

    Drug: SHR3680 · Drug: SHR3162

  • Experimental
    SHR3680+SHR3162(Placebo)

    Participants will receive SHR3680 combined with SHR3162(Placebo) orally

    Drug: SHR3680 · Drug: SHR3162(Placebo)

  • Placebo comparator
    SHR3680(Placebo)+SHR3162(Placebo)

    Participants will receive SHR3680(Placebo) combined with SHR3162(Placebo) orally

    Drug: SHR3680(Placebo) · Drug: SHR3162(Placebo)

Interventions

  • Tablet. Specifications of 80mg

  • Tablet. Specifications of 10mg、40mg、50mg and 100mg

  • DrugSHR3680(Placebo)

    Tablet. Specifications of 80mg

  • DrugSHR3162(Placebo)

    Tablet. Specifications of 10mg、40mg、50mg and 100mg

06

What researchers measure

Primary outcomes

  1. Adverse Event(AE)

    The type, frequency, severity, timing, seriousness, and relationship to study therapy

    Time frame: Approximately 70 months

  2. Overall Survival(OS)

    Time from randomisation to death due to any cause

    Time frame: Approximately 70 months

Secondary outcomes

  1. Time to prostate specific antigen (PSA) progression

    Time from randomisation to the first time of PSA progression according to the criterion of PCGW3

    Time frame: Approximately 70 months

  2. Radiographic Progression Free Survival(rPFS)

    Time from randomisation to radiologically confirmed progressive disease or death due to any cause

    Time frame: Approximately 70 months

  3. Objective response rate (ORR)

    The percentage of patients with measureable disease at baseline who achieved a complete or partial response in their soft tissue disease using the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria

    Time frame: Approximately 70 months

  4. Time to skeletal-related events

    Time from randomisation to the first occurrence of a skeletal-related event. The skeletal-related event is defined as the occurrence of either pathological or clinical fracture, spinal cord compression, bone-related radiotherapy or surgery.

    Time frame: Approximately 70 months

  5. PSA response rate

    After the continuous therapy from randomisation to the end of the 12 weeks, the percentage of patients whose levels of PSA decreased by more than 50% compared with baseline.

    Time frame: Approximately 70 months

  6. Area Under the Curve (AUC)

    The single dose and multiple dose PK will be calculated as data permits including AUC

    Time frame: Approximately 12 months

  7. Maximum Observed Plasma Concentration (Cmax)

    The single-dose and multiple dose PK will be calculated as data permits including Cmax

    Time frame: Approximately 12 months

  8. Minimum Observed Plasma Concentration (Cmin)

    The single-dose and multiple dose PK will be calculated as data permits including Cmin

    Time frame: Approximately 12 months

07

Study locations

1 site
  • Ye Dingwei
    Shanghai, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2019 to primary completion in Aug 2021, 28 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2019
First posted
Sep 25, 2019
StartActual
Apr 8, 2019
Primary completionActual
Aug 31, 2021
CompletionActual
Aug 31, 2021
Last update
Jun 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04102124
Responsible party
Sponsor
First posted
Sep 25, 2019
Start date
Apr 8, 2019
Primary completion
Aug 31, 2021
Completion
Aug 31, 2021
Last update
Jun 24, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Rezvilutamide · Fluzoparib

Start the discussion